These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12640677)

  • 21. Mechanism of acridine-based telomerase inhibition and telomere shortening.
    Gunaratnam M; Greciano O; Martins C; Reszka AP; Schultes CM; Morjani H; Riou JF; Neidle S
    Biochem Pharmacol; 2007 Sep; 74(5):679-89. PubMed ID: 17631279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telomerase inhibition and telomere loss in BEL-7404 human hepatoma cells treated with doxorubicin.
    Zhang RG; Guo LX; Wang XW; Xie H
    World J Gastroenterol; 2002 Oct; 8(5):827-31. PubMed ID: 12378624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells.
    Izbicka E; Wheelhouse RT; Raymond E; Davidson KK; Lawrence RA; Sun D; Windle BE; Hurley LH; Von Hoff DD
    Cancer Res; 1999 Feb; 59(3):639-44. PubMed ID: 9973212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telomerase inhibition is a specific early event in salvicine-treated human lung adenocarcinoma A549 cells.
    Liu WJ; Zhang YW; Shen Y; Jiang JF; Miao ZH; Ding J
    Biochem Biophys Res Commun; 2004 Oct; 323(2):660-7. PubMed ID: 15369801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
    Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
    Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Berberine Inhibits Telomerase Activity and Induces Cell Cycle Arrest and Telomere Erosion in Colorectal Cancer Cell Line, HCT 116.
    Samad MA; Saiman MZ; Abdul Majid N; Karsani SA; Yaacob JS
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33450878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting human telomerase in cancer therapy.
    Huard S; Autexier C
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):577-87. PubMed ID: 12678725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative studies on the mechanism of cytotoxic action of novel platinum II complexes with pyrazole ligands.
    Ciesielska E; Szulawska A; Studzian K; Ochocki J; Malinowska K; Kik K; Szmigiero L
    J Inorg Biochem; 2006 Oct; 100(10):1579-85. PubMed ID: 16842854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Water-Soluble Ruthenium(II) Complexes with Chiral 4-(2,3-Dihydroxypropyl)-formamide Oxoaporphine (FOA): In Vitro and in Vivo Anticancer Activity by Stabilization of G-Quadruplex DNA, Inhibition of Telomerase Activity, and Induction of Tumor Cell Apoptosis.
    Chen ZF; Qin QP; Qin JL; Zhou J; Li YL; Li N; Liu YC; Liang H
    J Med Chem; 2015 Jun; 58(11):4771-89. PubMed ID: 25988535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of telomerase activity in endometrial cancer cells by selenium-cisplatin conjugate despite suppression of its DNA-damaging activity by sodium ascorbate.
    Błasiak J; Kadłubek M; Kowalik J; Romanowicz-Makowska H; Pertyński T
    Teratog Carcinog Mutagen; 2002; 22(1):73-82. PubMed ID: 11754389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting telomeres and telomerase.
    De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
    Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A scalable and reproducible preparation for the antitumor protein TLC, a human-derived telomerase inhibitor.
    Chen G; Zhang X; He W; Shao M; Gao Q; Li L; Zhao M; Zhou H
    Protein Expr Purif; 2021 Nov; 187():105942. PubMed ID: 34284069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin.
    Gan Y; Lu J; Yeung BZ; Cottage CT; Wientjes MG; Au JL
    AAPS J; 2015 Jan; 17(1):268-76. PubMed ID: 25425294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Telomerase antisense inhibition and chemotherapeutic combination treatments for the proliferation of endometrial cancer in vitro and in vivo].
    Chen XJ; Zheng W; Chen LL; Chen ZB; Wang SQ
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1721-5. PubMed ID: 15569435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.
    Chen CL; Chang DM; Chen TC; Lee CC; Hsieh HH; Huang FC; Huang KF; Guh JH; Lin JJ; Huang HS
    Eur J Med Chem; 2013 Feb; 60():29-41. PubMed ID: 23279865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telomerase inhibition by 3'-azido-2', 3'-dideoxynucleoside 5'-triphosphates and telomere shortening in human cultured cells by the corresponding nucleosides.
    Yamaguchi T; Liu X; Ogawara T; Inomata M; Saneyoshi M
    Nucleic Acids Symp Ser (Oxf); 2006; (50):271-2. PubMed ID: 17150922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, antiproliferative activities and telomerase inhibition evaluation of novel asymmetrical 1,2-disubstituted amidoanthraquinone derivatives.
    Lee CC; Huang KF; Lin PY; Huang FC; Chen CL; Chen TC; Guh JH; Lin JJ; Huang HS
    Eur J Med Chem; 2012 Jan; 47(1):323-36. PubMed ID: 22100139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydropyrazole derivatives as telomerase inhibitors: Structure-based design, synthesis, SAR and anticancer evaluation in vitro and in vivo.
    Wang Y; Cheng FX; Yuan XL; Tang WJ; Shi JB; Liao CZ; Liu XH
    Eur J Med Chem; 2016 Apr; 112():231-251. PubMed ID: 26900656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening of telomerase inhibitors.
    Kleideiter E; Piotrowska K; Klotz U
    Methods Mol Biol; 2007; 405():167-80. PubMed ID: 18369824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How to inhibit telomerase activity for cancer therapy.
    Kyo S; Inoue M
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):613-26. PubMed ID: 12678728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.